Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Natural product-inspired small molecules for sexual and mental health
Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug…
Biodiversity-derived protein data and AI models for biological design
Basecamp Research is a London-based biotech company that collects biological samples from extreme environments across more than 26 countries, building a proprietary metagenomic database of over ten billion novel protein sequences from more than one million previously unrecorded species. This dataset trains large AI…
Global biopharma with UK manufacturing, commercial and clinical operations
MSD is a global biopharmaceutical company discovering, developing, manufacturing and marketing medicines and vaccines across oncology, infectious disease, immunology, cardiometabolic disease and animal health. Its UK operations span pharmaceutical manufacturing at Cramlington, Northumberland, which supplies medicines…
Global pharma company in immunology, vaccines, and oncology
GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines.…
Clinical-stage antifungal drug developer targeting invasive fungal infections
F2G is a clinical-stage biopharmaceutical company developing novel antifungal therapies for life-threatening invasive fungal infections. The company discovered the orotomides, a new class of antifungal agents that selectively inhibit fungal dihydroorotate dehydrogenase, a mechanism of action distinct from all approved…
Brain-inspired AI platform for multi-target drug discovery
Symbiotic.blue is a pre-seed biotech company developing an AI-driven drug discovery platform that combines generative AI with neuroscience-inspired computational methods. The platform aims to design molecules capable of acting on multiple biological targets simultaneously, with an initial focus on obesity. The company…
Preventing cancer therapy side effects with topical medicines
VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective…
Investigational oral ketamine formulations for treatment-resistant depression
Neurocentrx Pharma is a clinical-stage biopharmaceutical company developing oral ketamine formulations for treatment-resistant mood disorders. Its NRCx-201 programme includes immediate-release and abuse-deterrent capsules intended for clinically supervised treatment and potentially supported home care. Following…
Fibroblast immunology platform targeting cancer and inflammatory disease
Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies that target activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a FAP-targeted LTBR agonist bispecific antibody designed to induce tertiary…
Generative AI platform for TCR therapy design and immune repertoire analysis
Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction…
Clinical-stage CNS drug discovery using human brain genomics
Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue…
Transformative medicines for cystic fibrosis and serious genetic diseases
Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has…
Oral and injectable peptide therapies for obesity and cardiometabolic disease
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology…
Next-generation lateral CAR-T therapies for refractory solid tumours
Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology. Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases.…
Immunomodulatory therapeutics for chronic autoimmune and inflammatory diseases
Kherion Technology is a biotechnology company developing immunomodulatory treatments for chronic autoimmune and inflammatory diseases. Its lead preclinical programme investigates a proprietary therapeutic composition intended to reduce chronic inflammation without broadly suppressing immune activity. A granted US…
Engineered patient cells for sustained therapeutic antibody production
Semper-B Therapeutics is a biotechnology company developing a cell-engineering platform intended to enable patients’ own cells to produce therapeutic antibodies over prolonged periods. The approach aims to achieve durable, precise modulation of immune activity by using engineered cells as a continuing source of…
UK commercial base for a rare metabolic disease biotech
Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK…